Chemo into the liver plus IV chemo for bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a treatment plan that first delivers chemotherapy directly into the liver (through a thin tube) along with standard IV chemotherapy. The goal is to shrink the tumor enough to allow for surgery or less aggressive treatment later. It is for people with bile duct or gallbladder cancer that has not spread far.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with bile duct or gallbladder cancer that has not spread widely.
- You have not received any cancer treatment yet for this diagnosis.
- You are generally healthy (able to care for yourself and up and about more than half the day).
- Your liver function is good enough, based on blood tests.
- You do not have any other cancer, a history of organ transplant, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of four drugs—two immunotherapy drugs (iparomlimab and toripalimab), a targeted therapy (bevacizumab), and chemotherapy—as a first-line treatment for advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of chemotherapy directly to the liver, a targeted therapy pill, and an immunotherapy drug for people with advanced bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a combination of chemotherapy drugs given directly into the liver, combined with two immunotherapy/targeted therapy drugs, for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to shrink tumors and improve survival in patients who have not received prior chemotherapy.
This trial tests combining two drugs (adebrelimab and lenvatinib) with a liver-directed chemotherapy infusion (HAIC) to shrink locally advanced bile duct or gallbladder cancers enough to allow surgery. It is for people who haven't had prior treatment for their biliary cancer and whose cancer has not spread far.
This trial tests a combination of a targeted drug (lenvatinib), an immunotherapy (PD-1 inhibitor), and chemotherapy given directly into the liver's blood supply for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer that starts in the liver). The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of three treatments—chemotherapy delivered directly to the liver, plus two immunotherapy drugs—for advanced bile duct cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment and is safe for patients.
Hear when a new Biliary Tract Cancer (BTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.